Evidence map›Paper›PMID 41608134›Full record

ArticleLeukemia research reports2026

Pancreatitis induced by Peg-aspargase in children: a real-world pharmacovigilance analysis based on FDA Adverse Event Reporting System (FAERS).

Wenwen Zhang, Bin Luo, Zhuo Liu, Jie Mi, Yanping Yang, Yuan Li

Abstract read
In one paragraph

Article in Leukemia research reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Wenwen ZhangDepartment of Pharmacy, Xi'an Children's Hospital, The Affiliated Children Hospital of Xi'an Jiaotong University, Xi'an, China.
Bin LuoDepartment of Urology, Xijing Hospital, The AirForce Medical University, Xi'an, China.
Zhuo LiuDepartment of Pharmacy, Xi'an Children's Hospital, The Affiliated Children Hospital of Xi'an Jiaotong University, Xi'an, China.
Jie MiDepartment of Pharmacy, Xi'an Children's Hospital, The Affiliated Children Hospital of Xi'an Jiaotong University, Xi'an, China.
Yanping YangDepartment of Pharmacy, Xijing Hospital, The AirForce Medical University, Xi'an, China.
Yuan LiDepartment of Pharmacy, Xi'an Children's Hospital, The Affiliated Children Hospital of Xi'an Jiaotong University, Xi'an, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This study analyzed FAERS data to evaluate pegaspargase safety in pediatric acute lymphoblastic leukemia treatment. Among 21,161,817 reports, 847 identified pegaspargase as the primary suspect drug, revealing adverse events (AEs) across 26 organ systems. Disproportionality analysis identified four previously unlisted AEs. Critically, pegaspargase-associated pancreatitis incidence showed significant age-dependence (χ²=8.219,

Indexed as

Acute lymphoblastic leukemiaAdver drug reactionsChildrenPancreatitisPegaspargase

Identifiers

PMID41608134
PMCPMC12834836

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.